CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

News Charles River Laboratories International, Inc. Berne S.E.

Stocks

RV6

US1598641074

Biotechnology & Medical Research

End-of-day quote Berne S.E. Other stock markets 2026-08-07			5-day change	1st Jan Change
213.32 ^CHF	+1.55%		+14.16%	-

Aug. 06	Charles River Laboratories International Insider Sold Shares Worth $1,327,098, According to a Recent SEC Filing	MT
Aug. 06	Barclays Adjusts Price Target on Charles River Laboratories International to $300 From $220	MT

All News

Mentions Relevance

Aug. 06	Charles River Laboratories International Insider Sold Shares Worth $1,327,098, According to a Recent SEC Filing	MT
Aug. 06	Barclays Adjusts Price Target on Charles River Laboratories International to $300 From $220	MT
Aug. 06	RBC Adjusts PT on Charles River Laboratories International to $282 From $215, Keeps Outperform Rating	MT
Aug. 06	Deutsche Bank Adjusts Charles River Laboratories International PT to $300 From $260, Maintains Buy Rating	MT
Aug. 06	JPMorgan Upgrades Charles River Laboratories International to Overweight From Neutral, Adjusts PT to $310 From $180	MT
Aug. 05	Top Midday Gainers	MT
Aug. 05	Charles River Laboratories International, Inc., Q2 2026 Earnings Call, Aug 05, 2026
Aug. 05	Tranche Update on Charles River Laboratories International, Inc.'s Equity Buyback Plan announced on November 5, 2025.	CI
Aug. 05	Charles River Laboratories International, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 27, 2026	CI
Aug. 05	Charles River Laboratories Fiscal Q2 Non-GAAP Earnings, Revenue Fall; Lifts 2026 Guidance	MT
Aug. 05	Charles River Laboratories International, Inc. Updates Earnings Guidance for 2026	CI
Aug. 05	(CRL) Charles River Laboratories Expects 2026 Adjusted EPS Range $11.15 - $11.45, vs. FactSet Est of $11.11	MT
Aug. 05	Earnings Flash (CRL) Charles River Laboratories Posts Fiscal Q2 Revenue $1.00B, vs. FactSet Est of $977.2M	MT
Aug. 05	Earnings Flash (CRL) Charles River Laboratories Posts Fiscal Q2 Adjusted EPS $3.02, vs. FactSet Est of $2.74	MT
Aug. 05	Charles River lifts profit forecast on improving biotech demand	RE
Aug. 05	Charles River: Q2 Earnings Snapshot	AQ
Aug. 05	Charles River Laboratories Announces Second-Quarter 2026 Results	BU
Jul. 15	Charles River Laboratories Schedules Second-Quarter 2026 Earnings Release and Conference Call	BU
Jul. 13	BofA Adjusts Price Target on Charles River Laboratories International to $264 From $220	MT
Jul. 13	Baird Adjusts Charles River Laboratories International Price Target to $255 From $213, Maintains Outperform Rating	MT
Jul. 13	Charles River Laboratories to Provide Cell Sequencing Services to Arovella Therapeutics	MT
Jul. 13	Charles River Provides Ngs Services to Arovella Therapeutics, Accelerating Progress Toward Alternative Cancer Treatment Approaches	CI
Jul. 13	Mizuho Adjusts Price Target on Charles River Laboratories International to $230 From $192, Maintains Neutral Rating	MT
Jul. 13	Charles River Provides NGS Services to Arovella Therapeutics, Accelerating Progress Toward Alternative Cancer Treatment Approaches	BU
Jul. 09	Morgan Stanley Adjusts Price Target on Charles River Laboratories International to $260 From $220	MT